Correlation Engine 2.0
Clear Search sequence regions

  • africa (1)
  • capsules (1)
  • children (4)
  • disease and (1)
  • female (1)
  • gambia (5)
  • haemophilus (1)
  • haemophilus vaccines (2)
  • humans (1)
  • infant (2)
  • patients (1)
  • vaccines (2)
  • Sizes of these terms reflect their relevance to your search.

    Haemophilus influenzae type b (Hib) conjugate vaccine was first introduced in Africa in The Gambia in 1997 as a primary 3-dose course in infancy with no booster, and was followed by the disappearance of invasive Hib disease by 2002. A cluster of cases detected non-systematically in post-infant children in 2005-2006 raised the question of the need for a booster dose. The objective of this study was to determine the incidence of invasive Hib disease in Gambian children 14 years after the introduction of Hib conjugate vaccine. This hospital-based clinical and microbiological Hib disease surveillance in 3 hospitals in the western region of The Gambia was undertaken between October 2007 and December 2010 applying the same methods used in a previous Hib vaccine effectiveness study in 1997-2002. The annual incidences of Hib meningitis and all invasive Hib disease in children aged <5 years remained below 5 cases per 100,000 children during 2008-2010. The median age of patients with any invasive Hib disease was 5 months. Hib conjugate vaccination as a primary 3-dose course in The Gambia remains highly effective in controlling invasive Hib disease, and current data do not support the introduction of a booster dose. Copyright © 2013. Published by Mosby, Inc.


    Claire Oluwalana, Stephen R C Howie, Ousman Secka, Readon C Ideh, Bernard Ebruke, Sana Sambou, James Erskine, Yamundow Lowe, Tumani Corrah, Richard A Adegbola. Incidence of Haemophilus influenzae type b disease in The Gambia 14 years after introduction of routine Haemophilus influenzae type b conjugate vaccine immunization. The Journal of pediatrics. 2013 Jul;163(1 Suppl):S4-7

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 23773593

    View Full Text